Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer

We developed a novel therapeutic radioligand, [Lu-177]1h, with an albumin binding motif and evaluated it in a prostate-specific membrane antigen (PSMA)-expressing tumor xenograft mouse model. Fourteen PSMA target candidates were synthesized, and binding affinity was evaluated with an in vitro competitive binding assay. First, four compound candidates were selected depending on binding affinity results. Next, we selected four compounds ([Ga-68]1e, [Ga-68]1g, [Ga-68]1h, and [Ga-68]1k) were screened for tumor targeting efficiency by micro-positron emission tomography/computed tomography (micro-PET/CT) imaging. Finally, [Lu-177]1h compound was evaluated the tumor targeting efficiency and therapeutic efficiency by micro-single-photon emission computed tomography/computed tomography (micro-SPECT/CT), biodistribution, and radiotherapy studies. Estimated human effective dose was calculated by biodistribution data. Compound 1h showed a high binding affinity (K-i value = 4.08 +/- 0.08 nmol/L), and [Lu-177]1h showed extended blood circulation (1 hour = 10.32 +/- 0.31, 6 hours = 2.68 +/- 1.07%1D/g) compared to [Lu-177]PSMA-617 (1 h = 0.17 +/- 0.10%ID/g). [Lu-177]1h was excreted via the renal pathway and showed high tumor uptake (24.43 +/- 3.36%ID/g) after 1 hour, which increased over 72 hours (72 hours = 51.39 +/- 9.26%ID/g). Mice treated with 4 and 6 MBq of [Lu-177]1h showed a median survival rate of >61 days. In particular, all mice treated with 6 NA Rq of [Lu-177]1h survived for the entire monitoring period. The estimated human effective dose of [Lu-177]1h was 0.07 +/- 0.01 and 0.03 +/- 0.00 mSv/MBq in total body and kidney, respectively. The current study indicates that [Lu-177]1h has the potential for further investigation of metastatic castration-resistant prostate cancer (mCRPC) therapy in clinical trials.